Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06026449

Gluten-free Diet in PSC and IBD

Conditions: Primary Sclerosing Cholangitis, Ulcerative Colitis, Biliary Tract Diseases, Biliary Disease Tract, Intestinal Disease

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: NA
Enrollment: 51
Sponsor: Institute for Clinical and Experimental Medicine

Location: Institute of clinical and experimental medicine Prague

Summary

Primary sclerosing cholangitis (PSC) is a progressive disease of the biliary tree, which represents one of the most frequent indications for orthotopic liver transplantation (OLTx) in developed countries. There are several lines of evidence that dietary gluten/gliadin displays chronic pro-inflammatory, LPS-like properties. Recent evidence demonstrated the protective effect of gluten- free diet (GFD) in autoimmune diseases like type 1 diabetes, irritable bowel syndrome, non-celiac gluten sensitivity and some neurological disorders. This study is intended to explore therapeutic effect of GFD on PSC and IBD in prospective self-controlled mono-centric intervention study. Hypothesis: Avoidance of gluten in diet will reduce progression, symptoms and intestinal inflammation in PSC and UC patients.

Eligibility Criteria

Inclusion Criteria (for PSC group): * Established diagnosis of PSC (based on radiologic features, typical finding on MRCP or ERCP) * Age 18 - 65 years * ALP 1,5x higher than ULN * Signed informed consent Exclusion Criteria (for PSC group): * Patients on gluten-free diet * Patients with coeliac disease or wheat allergy * Liver transplant recipients * PSC/AIH overlap syndrome * Other causes of liver disease * Radiologic or clinical signs of decompensated liver cirrhosis * Advanced liver cirrhosis (MELD score ˃ 15) * Recurrent acute cholangitis or cholangiogenic sepsis in past 3 months * Use of antibiotics in past 3 months * History of malignancy * Pregnant women * Not signed informed consent Inclusion criteria (for UC group): * Ulcerative colitis diagnosed based on clinical, endoscopic and histological findings * Extension of affected colon \> 15cm * Mayo score 0-4 * Signed informed consent Exclusion criteria (for UC group): * CMV, Clostridium difficile enterocolitis in past 3 months * Use of antibiotics in past 3 months * Patients with coeliac disease or wheat allergy * Patients on gluten-free diet * Pregnant women * Not signed informed consent * Biologic therapy * Methotrexate * Prednison \> 10 mg * Not signed informed consent

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06026449). StuddyBuddy aggregates publicly available trial information.